Company Overview
Liquidia Corporation operates within the Healthcare sector, specifically serving the Drug Manufacturers - Specialty & Generic industry by developing, manufacturing, and commercializing products for rare cardiopulmonary diseases in the United States. The company's primary focus is on lead product candidates such as YUTREPIA, which is an inhaled dry powder formulation of treprostinil designed for the treatment of pulmonary conditions. As of the latest data, the company possesses a market capitalization of $3.29B and reports annual revenue of $158.32M, employing a workforce of 216 individuals. These valuation and revenue figures position Liquidia as a mid-cap biopharmaceutical entity with significant market potential, though the high multiple relative to sales suggests the market prices in substantial future growth expectations rather than current operational profitability. The scale of the company, reflected in its $3.29B market cap, indicates that investors view the rare disease therapeutic space as a high-value domain where current financial metrics may lag behind the perceived long-term value of its drug portfolio.
Financial Health
The company reports a trailing twelve-month revenue of $158.32M, yet this generates a net income of -$68,924,000 and an EBITDA of -$50,348,000. The substantial gap between positive revenue of $158.32M and negative net income reveals a cost structure dominated by high operating expenses, likely including research and development costs and commercialization efforts typical of biopharmaceutical firms in the growth phase. Free cash flow stands at -$43,121,500, indicating that current cash generation is insufficient to cover operational expenditures and capital investments, which limits immediate financial flexibility for large-scale acquisitions or aggressive expansion without external funding. Despite the negative cash flow, the company holds $190.68M in cash against total debt of $197.93M, resulting in a debt-to-equity ratio of 442.31. This leverage level suggests a highly leveraged balance sheet, where debt obligations significantly exceed equity capital, a common scenario for pre-profitability biotech companies relying on future asset monetization. However, the current ratio of 2.01 indicates a robust short-term liquidity position, meaning the company has more than twice the current assets necessary to cover its current liabilities. Return on Equity is recorded at -111.1% and Return on Assets at -11.5%, metrics that reveal management is currently not generating positive returns on capital deployed, reflecting the heavy investment phase required to bring specialty drugs to market before achieving profitability.
Valuation Assessment
The valuation metrics show a P/E Ratio (TTM) as N/A due to negative earnings, while the Forward P/E is 7.75. The absence of a trailing P/E combined with a forward P/E of 7.75 implies that the market expects earnings to turn positive in the future, projecting a significant trajectory from current losses. The price-to-book ratio is an exceptionally high 72.83, indicating a massive market premium over the company's book value, which suggests investors are pricing in the intangible value of intellectual property and future patent exclusivity rather than tangible assets. Alternative valuation metrics include a price-to-sales ratio of 20.79 and an EV/EBITDA of -65.53. The price-to-sales ratio of 20.79 suggests the market is willing to pay a premium for every dollar of revenue, while the negative EV/EBITDA of -65.53 confirms that traditional earnings-based valuation models are not applicable until profitability is achieved. The stock trades between a 52-week high of $46.67 and a 52-week low of $11.26. The current trading price sits within this range, reflecting volatility typical of small-cap biopharmaceutical stocks where news regarding clinical trials or regulatory approvals can cause rapid price swings. The beta value of 0.56 indicates that the stock is less volatile than the broader market, moving with less intensity than the overall index despite its sector-specific risks.
Growth & Income
Revenue growth over the year is reported at 3054.6%, while earnings growth is N/A due to the lack of positive earnings history. This disparity implies that revenue expansion is occurring rapidly, likely driven by the launch of new products or market uptake of existing therapies, whereas earnings are still being suppressed by structural costs. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%. The zero payout ratio confirms that the company reinvests all available earnings and cash reserves back into research, development, and commercialization rather than distributing income to shareholders. This approach is standard for companies in the drug manufacturing sector that require continuous capital investment to sustain pipeline growth and regulatory compliance. The overall growth and income profile characterizes Liquidia as a high-growth, non-income stock where shareholder returns are expected to materialize only after the company achieves sustained profitability and positive cash flow generation.